Literature DB >> 23549149

Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.

F Ehmann1, M Papaluca Amati, T Salmonson, M Posch, S Vamvakas, R Hemmings, H G Eichler, C K Schneider.   

Abstract

This article analyzes the role of regulatory authorities in facilitating innovation in the pharmaceutical sector. We describe how regulators are expanding their role to be not only gatekeepers but also enablers of development. They have already responded to the challenging and changing environment by moving toward a proactive attitude beyond evaluation of products, thereby more actively contributing to their development. Regulators have to continuously evolve their knowledge and standards alongside evolution in science. Creation of supportive regulatory frameworks and multistakeholder interaction will help address unmet regulatory needs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549149     DOI: 10.1038/clpt.2013.14

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Model-based clinical drug development in the past, present and future: a commentary.

Authors:  Holly Kimko; José Pinheiro
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 2.  European Medicines Agency initiatives and perspectives on pharmacogenomics.

Authors:  Falk Ehmann; Laura Caneva; Marisa Papaluca
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

3.  Nanomedicines in the EU-Regulatory Overview.

Authors:  Ruben Pita; Falk Ehmann; Marisa Papaluca
Journal:  AAPS J       Date:  2016-08-15       Impact factor: 4.009

Review 4.  Applications of pharmacogenomics in regulatory science: a product life cycle review.

Authors:  W C Tan-Koi; P C Leow; Y Y Teo
Journal:  Pharmacogenomics J       Date:  2017-12-05       Impact factor: 3.550

5.  E-Synthesis: A Bayesian Framework for Causal Assessment in Pharmacosurveillance.

Authors:  Francesco De Pretis; Jürgen Landes; Barbara Osimani
Journal:  Front Pharmacol       Date:  2019-12-17       Impact factor: 5.810

6.  The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions.

Authors:  Magdalena Bujar; Neil McAuslane; Lawrence Liberti
Journal:  Pharmaceut Med       Date:  2021-02-04

7.  Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and Beyond.

Authors:  Natalie M Hendrikse; Jordi Llinares Garcia; Thorsten Vetter; Anthony J Humphreys; Falk Ehmann
Journal:  Front Med (Lausanne)       Date:  2022-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.